10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
China-based biotech start-up I-Mab Biopharma today announces that it has entered into a memorandum of understanding (MoU) with Hong Kong-based Bio-Cancer Treatment International (BCT) to jointly explore and investigate new therapeutic potentials for BCT's arginine depletion therapy in autoimmune diseases and cancers. 1 February 2019
Danish biotech Genmabrevealed on Thursday that the patent infringement lawsuit launched by Germany-based MorphoSys relating to Darzalex (daratumumab) is finally over. 1 February 2019
Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) has been approved by the UK’s cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) for diffuse large B-cell lymphoma (DLBCL). 1 February 2019
Group sales climbed 7% to 56.8 billion Swiss francs ($57.2 billion) in full-year 2018, Swiss pharma giant Roche announced this morning. 31 January 2019
A report from industry analyst GlobalData suggests that AbbVie’s strong immunology pipeline will protect its grip on the plaque psoriasis and rheumatoid arthritis markets, while the workhorse Humira (adalimumab) loses ground to competition in Europe. 30 January 2019
Describing it as “an incomplete and poorly conceived report from the controversial Institute for Clinical and Economic Review,” the Institute for Patient Access (IfPA) says the ICER has set its sights on a most unbecoming target: infants with a degenerative, life-threatening neurological condition. 30 January 2019
US pharma majors Pfizer and Eli Lilly yesterday announced positive top-line results from a Phase III study evaluating tanezumab 2.5mg or 5mg in patients with moderate-to-severe osteoarthritis (OA) pain. 30 January 2019
Neurocrine Biosciences has entered a strategic collaboration focused on the development and commercialization of Voyager Therapeutics’ gene therapy programs. 30 January 2019
Shares of US biotech major Amgen dipped 2.43% to $187.45 in after-hours trading yesterday, when the company released its financial results for 2018. 30 January 2019
Shares in Japan’s SanBio are down a quarter after the firm announced that a US-based Phase IIb study of the investigational cell and gene therapy candidate SB623 has flopped. 30 January 2019
US biotech Biogen today posted full-year and fourth-quarter financial results for 2018. Full year total revenues were $13.5 billion, a 10% increase versus the prior year. 29 January 2019
Canada-based Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with US biotech major Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia. 29 January 2019
US drugmaker Alexion Pharmaceuticals announced that the Phase III study of Ultomiris (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome (aHUS). 29 January 2019
Imbruvica (ibrutinib) clocked up a third US Food and Drug Administration (FDA) approval in first-line chronic lymphocytic leukemia (CLL) on Monday, this time in combination with Gazyva (obinutuzumab). 28 January 2019
Results from a pooled analysis of four Phase III clinical trials demonstrating patients with moderate-to-severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early as Week 4 when compared to placebo in patients who reported problems at baseline. 28 January 2019
The Australian government said on Friday that it will make two new medicines for the treatment of the skin condition psoriasis more affordable, saving patients up to A$32,600 ($23.453) per year. 28 January 2019
The migraine market has seen a game-change with the approvals and launches of a new and much-anticipated class of therapy, calcitonin gene-related peptide (CGRP) inhibitors. 28 January 2019